Table 1 Patient characteristics of the two cohorts a
Baseline | Cohort 1 (N=180) | Cohort 2 (N=135) | P-value | ||
|---|---|---|---|---|---|
Age, yr | 55 | (27 to 78) | 52 | (26 to 71) | 0.11 |
Female sex | 66% | 65% | 0.91 | ||
Disease duration, days | 84 | (42 to 162) | 98 | (48 to 175) | <0.001 |
Rheumatoid factor-positive, % | 72% | 68% | 0.54 | ||
Anti-CCP-positive, % | 65% | 60% | 0.41 | ||
Tender joint count | 11 | (3 to 26) | 9 | (2 to 22) | 0.07 |
Swollen joint count | 8 | (2 to 23) | 8 | (2 to 20) | 0.41 |
Patient global assessment, mm | 67 | (13 to 98) | 50 | (10 to 91) | <0.001 |
CRP, mg/L | 14 | (1 to 132) | 20 | (2 to 105) | 0.04 |
DAS28 score | 5.6 | (3.8 to 7.7) | 5.3 | (3.2 to 7.1) | 0.02 |
HAQ | 1.1 | (0.1 to 2.5) | 1.0 | (0 to 2.3) | 0.02 |
Year 1 | |||||
CRP, mg/L | 2 | (0.5 to 19) | 7 | (0.7 to 33) | <0.001 |
DAS28 score | 2.0 | (1.7 to 4.3) | 2.0 | (1.3 to 5.1) | 0.13 |